Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.40 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.40 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.40 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.40 |
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxalic Acid SCHEMBL4519228 | 0.94 | CYP2D6 (0.39) | MAOB | |
| SCHEMBL954722 | 0.84 | SIGMAR1 (0.58) | SIGMAR1CARM1PRMT6PRMT8HTR6 | |
| Oxalic Acid SCHEMBL956463 | 0.80 | SIGMAR1 (0.53) | SIGMAR1 | |
| SCHEMBL958098 | 0.79 | SIGMAR1 (0.57) | SIGMAR1CARM1PRMT6PRMT8HTR6 | |
| SCHEMBL956607 | 0.78 | SIGMAR1 (0.44) | SIGMAR1CARM1PRMT6PRMT8HTR6 | |
| SCHEMBL4108724 | 0.78 | GRIN2B (0.47) | SIGMAR1CARM1PRMT6PRMT8 | |
| SCHEMBL955114 | 0.75 | SIGMAR1 (0.50) | SIGMAR1 | |
| SCHEMBL5170674 | 0.75 | SIGMAR1 (0.80) | SIGMAR1CARM1PRMT6HRH3 | |
| SCHEMBL4519230 | 0.74 | MEN1 (0.35) | HTR6 | |
| SCHEMBL4514469 | 0.73 | SIGMAR1 (0.38) | SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1996548-B1 | SIGMA RECEPTOR COMPOUNDS | ESTEVE LABOR DR (ES) | 2016-01-06 | — | — | EP | claimed |
| US-8481567-B2 | Sigma receptor compounds | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2013-07-09 | — | — | US | claimed |
| US-20090197915-A1 | SIGMA RECEPTOR COMPOUNDS | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2009-08-06 | — | — | US | claimed |
| EP-1996548-A1 | SIGMA RECEPTOR COMPOUNDS | Laboratorios del Dr. Esteve S.A. (ES) | 2008-12-03 | — | — | EP | claimed |
| WO-2007098962-A1 | SIGMA RECEPTOR COMPOUNDS | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2007-09-07 | — | — | WO | claimed |
| EP-1996548-B1 | SIGMA RECEPTOR COMPOUNDS | ESTEVE LABOR DR (ES) | 2016-01-06 | — | — | EP | disclosed |
| EP-1996548-B1 | SIGMA RECEPTOR COMPOUNDS | ESTEVE LABOR DR (ES) | 2016-01-06 | — | — | EP | disclosed |
| US-8481567-B2 | Sigma receptor compounds | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2013-07-09 | — | — | US | disclosed |
| US-8481567-B2 | Sigma receptor compounds | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2013-07-09 | — | — | US | disclosed |
| US-8481567-B2 | Sigma receptor compounds | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2013-07-09 | — | — | US | disclosed |
| US-20090197915-A1 | SIGMA RECEPTOR COMPOUNDS | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2009-08-06 | — | — | US | disclosed |
| US-20090197915-A1 | SIGMA RECEPTOR COMPOUNDS | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2009-08-06 | — | — | US | disclosed |
| US-20090197915-A1 | SIGMA RECEPTOR COMPOUNDS | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2009-08-06 | — | — | US | disclosed |
| EP-1996548-A1 | SIGMA RECEPTOR COMPOUNDS | Laboratorios del Dr. Esteve S.A. (ES) | 2008-12-03 | — | — | EP | disclosed |
| WO-2007098962-A1 | SIGMA RECEPTOR COMPOUNDS | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2007-09-07 | — | — | WO | disclosed |
| WO-2007098962-A1 | SIGMA RECEPTOR COMPOUNDS | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2007-09-07 | — | — | WO | disclosed |
| EP-1829862-A1 | Sigma receptor compounds | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-09-05 | — | — | EP | disclosed |
| EP-1829862-A1 | Sigma receptor compounds | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-09-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197915-A1 | SIGMA RECEPTOR COMPOUNDS | SIGMAR1, OPRL1, OPRK1 | SIGMAR1 1/4885CARM1 4090/4885PRMT6 3662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.